Recent Development

 

 

 

Our target –

Serving emerging

companies

Recent Development

 We will post what we believe is some of the most interesting news in the technology sector of the last week + some of the basic projects updates we work on + updates on recent topics of our recent newsletters

Pharma update

Drug finding “Despite enormous investments in basic science, technology development, and experimentation with new organizational and management structures, pharmaceutical product development still requires at least 10 to 15 years and costs between $500 millionand $2 billion (1, 2). Furthermore, there is a widening productivity gap: Research and developmen spending continues to increase, yet the number of new therapeutic chemical and biological entities approved by the U.S. Food and Drug Administration (FDA) has been declining since the late 1990s (3). Overcoming these and other obstacles to increased productivity may require an overhaul of the R&D paradigm (4); some have called for a "disruptive" transformation of the industry (5)”.

  • Biological drugs: Drugs of the future - “Biologic drugs are large, complex molecules derived from living organisms. Recently, U.S. sales of biologic drugs exceed $40 billion annually and global sales were over $112 billion. Sales are concentrated among a few blockbuster products as just 27 biologic products represent approximately 87 percent of total biologic drug sales”.
  • The growing allure of rational drug desing: Structure-based approaches for drug design and virtual screening give new meaning to Louis Pasteur's saying "Chance favors the prepared mind." In silico methods are becoming more efficient in allowing scientists to hone in on and manipulate specific molecular structures of interest.

  • Pharmacogenomics: the promise of personalized medicine: ”Pharmacogenetics identifies interactions between drugs and individual genes. Pharmacogenomics seeks to uncover significant associations between genomic patterns and clinical outcomes—correlations that produce useful predictive knowledge, allowing clinical treatment decision making to be based upon more rational criteria than today's probabilistic approach, which is largely based upon educated guesswork.”

  • Drug-diagnostic Co-development: “The development of genomics-based molecular diagnostics that are linked to therapeutic products is critical to targeted drug developments of the future.” There is a growing trend for co-development partnerships to be made during the early stages of drug development. An analysis of ongoing co-development projects indicates that more deals are being concluded well in advance of Phase."

  • New DNA And RNA Aptamers Offer Unique Therapeutic: "A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases."

  • High-performance, Low-cost Imaging Modalities Gain Appeal in Life Sciences Arena http://www.researchandmarkets.com/research/6eb7b8/european_market_fo

  • Drugmakers will make ‘aggressive changes’ to R&D this year, say researchers

Stem Cell

  • Stem cells are how we all begin “Few quarrel with predictions of the awesome potential that stem cell research holds. One day, scientists say, stem cells may be used to replace or repair dam-aged cells, and have the potential to drastically change the treatment of conditions like cancer, Alzheimer's and Parkinson's disease and even pa-ralysis. But the divisions over how to conduct that research have been deep and bitter.”  NYTimes.com
  • Remarkable progress in understanding how stem cell biology works has been reported by a team of leading scientists, directed by experts at UC Santa Barbara. Their research has been published in the journal Cell Stem Cell. Sciencedaily.com
  • Green light for first embryonic stem cell treatment in spinal cord in humans (*) ”It has taken more than five years of slog, but at long last approval has been given for the first clinical trial using human embryonic stem cells (hESCs). These cells can develop into all tissues of the body ….to use cells derived from hESCs to treat people with acute spinal cord injuries”. Newscientist.com
  • Pluristem stem cell therapy saves a patient, shares jump - Pluristem Therapeutics Inc said a 7-year old girl suffering from a bone marrow disease experienced a reversal of her condition after receiving its experimental stem cell therapy, sending the Israeli company's shares up 32 percent.

 

Solar power -

"With the emergence of low-cost thin-film solar, the rapid evolution of concentrator photovoltaics, and the increased capabilities of thermal solar concentration systems, the solar energy industry has begun to shine brightly". Higgins, James M (http://www.futurist.com).

  • Solar power - As oil prices have climbed, so has venture investment in alternative energy. According to VentureDeal, a venture-tracking service in Menlo Park, CA, solar-power startups in particular have seen a three-year surge, from a low of no venture investment in the third quarter of 2005 to a high of more than half a billion dollars in the second quarter of 2008.
  • Solar power at night – storing solar power for night time. "Without a good way to store electricity on a large scale, solar power is useless at night. One promising storage option is a new kind of battery made with all-liquid active materials. Prototypes suggest that these liquid batteries will cost less than a third as much as today's best batteries and could last significantly longer."
  • Prism has engineered a new type of solar concentrator by inscribing holograms in a transparent medium sealed between pieces of glass. Much of the light that strikes a conventional solar cell generates wasted heat rather than electricity, but Prism's holograms can divert unproductive wavelengths of light away from the cell. As a consequence, it can concentrate the productive wavelengths more intensely without fear of overheating. The company claims that it can concentrate light two to three times as much as its competitors can.
  • CaliSolar - Most solar cells are made from very pure--and thus expensive--silicon. But ­CaliSolar can make do with silicon that has a thousand times the impurities and can cost a sixth as much. That could mean real savings, since silicon can represent a quarter to a third of the cost of making solar cells.

Web 3.0

Web 2.0 is about social networking and mass collaboration. Web 3.0 is based on “intelligent” web applications using: Natural language processing, Machine-based learning and reasoning, Intelligent applications. We are currently looking at "Intelligent" applications that can create intelligent information in various forms from the net and in the process improve themselves.

  • The Web Is Reborn - The last decade expanded what we could do online, but the Web's basic programming couldn't keep up. That threatened to fracture the world's greatest innovation engine—until a small group of Web rivals joined forces to save it. Technologyreview.com
  • The Great Mobile Cloud Disruption - A new crop of mobile software startups is changing the way enterprises choose software, at the expense of big players like Microsoft. Technologyreview.com

 

Bacterial Technology

Gulf Oil Spill: Methane Gas Concentrations in Gulf of Mexico Quickly Returned to Near-Normal Levels, Surprising Researchers  - Calling the results "extremely surprising," researchers from the University of California, Santa Barbara and Texas A&M University report that methane gas concentrations in the Gulf of Mexico have returned to near normal levels only months after a massive release occurred following the Deepwater Horizon oil rig explosion.

 

 

Education revolution

 

Harvard and M.I.T. Team Up to Offer Free Online Courses - " In what is shaping up as an academic Battle of the Titans — one that offers vast new learning opportunities for students around the world — Harvard and the Massachusetts Institute of Technology on Wednesday announced a new nonprofit partnership, known as edX, to offer free online courses from both universities." NYT

 

MIT and Harvard launch a ‘revolution in education’ -"The new venture, called edX, will provide interactive classes from both Harvard and MIT — for free — to anyone in the world with an Internet connection. But a key goal of the project, Faust said, is “to enhance the educational experience of students who study in our classrooms and laboratories."

News And Articles

Recommendation - Tomer

I've had the pleasure to work with Dan for a number of years on various projects… »

CBS WW Event - June 12th, 2011- summary

We'd like to thank our sponsors for their generous support of this event: Coca … »

York Capital - Psagot Ofek

Dan Aridor Holdings Ltd assisted York Capital in the purchase of Psagot Offek fr… »

Drug Discovery - AEBI

Dan Aridor Holdings completed an investment round in a company that engaged in t… »

Recommendation - Yaron Kopel

»

Semiconductor

Dan Aridor Holdings Ltd assisted in an investment rounds in a technology that wa… »

Incubators

Dan Aridor Holdings assisted in privatization of two Israeli incubators. … »

Hefestus

»

Open Sky committee

Dan Aridor completed economic consulting services to the Israeli Open Sky commit… »

Multi-core processing

Dan Aridor Holdings Ltd assisted in raising funds for a multi-core processing co… »

Site Map   Home Page     Current Focus / Recent Development / Key People / Contact   Contact Dan D. Aridor
+972-3-6871341
Site By: Come2us